MedTrace Logo

First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

NCT04622774 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-01-15

Study results available
· View outcomes & findings →

Summary

This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

IMGC936

Antibody Drug Conjugate

Sponsors & Collaborators

  • MacroGenics

    collaborator INDUSTRY

  • ImmunoGen, Inc.

    lead INDUSTRY

Principal Investigators

  • CMO ImmunoGen · ImmunoGen, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2023-12-28
Completion
2023-12-28
FDA Drug
Yes

Countries

  • United States
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04622774 on ClinicalTrials.gov